Dermcidin: Physiology and What Research Reports

What is dermcidin?

Dermcidin is a human secreted protein encoded by the DCD gene. Unlike most human antimicrobial peptides, which are produced by epithelial cells and immune cells in response to injury or infection, dermcidin is best known as a constitutively secreted component of eccrine sweat. After secretion, the full-length precursor is cut by proteases on the skin surface into a family of smaller peptides, and it is these fragments — rather than the intact precursor — that carry most of the antimicrobial activity described in the literature. A 2015 review in International Journal of Medical Microbiology examined how dermcidin-derived peptides are generated and how they act against bacteria on human skin (PMID 25596890).

Because dermcidin is a natural human peptide precursor rather than a synthetic research compound, it appears in the peptide literature mainly as an object of study: a molecule whose sequence, processing and mechanism are investigated to understand innate immunity, skin biology and, more recently, tumour cell survival. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question.

Where dermcidin is produced

The dominant site of production described in the literature is the eccrine sweat gland, from which dermcidin reaches the skin surface dissolved in sweat. From there, surface proteases and the ionic environment of sweat shape which fragments are present and how active they are. Researchers have described dermcidin as unusual among human host-defense peptides precisely because its activity is tuned to a high-salt, slightly acidic sweat environment rather than to inflamed tissue (PMID 25596890).

Dermcidin expression is not limited to skin. A 2012 review in Journal of Innate Immunity surveyed what the authors called the multiple facets of dermcidin, spanning roles in cell survival as well as host defense, indicating that the gene and its products have been detected and studied well beyond the sweat gland (PMID 22455996). Dermcidin has also been measured in human milk: one 2019 study in Journal of Human Lactation quantified dermcidin alongside chemerin in human milk and reported alterations associated with gestational diabetes (PMID 31002762).

What dermcidin does in the body

Surface antimicrobial defense

The most established function is innate antimicrobial defense at the skin barrier. Dermcidin fragments act on bacterial membranes, and the 2015 mechanistic review focused on how this occurs, including the conditions under which the peptides assemble and permeabilise microbial targets (PMID 25596890).

A membrane pathway distinct from LL-37

Dermcidin is frequently compared with LL-37, the cathelicidin-derived human peptide. A 2017 biophysical study in Frontiers in Chemistry compared the two directly and reported that dermcidin and LL-37 follow novel, distinct pathways in their interactions with membranes, meaning two human peptides can reach antimicrobial outcomes by different physical routes (PMID 29164103). That comparison matters for peptide science generally, because it shows that sequence-level differences translate into measurably different membrane behaviour rather than a single shared mechanism.

Antiviral activity

Antiviral function is a more recent addition. A 2026 PNAS study reported that dermcidin has antiviral activity and protects against influenza, extending its described role beyond bacteria (PMID 41911454). This was preclinical work, and the paper did not establish any human therapeutic use.

Cell survival and cancer biology

Dermcidin also appears in oncology literature. A 2008 review in Current Opinion in Clinical Nutrition and Metabolic Care examined the dermcidin gene in cancer, covering its proposed roles in cachexia, carcinogenesis and tumour cell survival (PMID 18403914). Building on that line of work, a 2022 paper in Marine Drugs described preclinical development of seriniquinones as selective dermcidin modulators for the treatment of melanoma, treating dermcidin as a molecular target rather than as an administered peptide (PMID 35621952).

Pro-dermcidin and systemic immunity

A 2025 review in International Journal of Molecular Sciences discussed pro-dermcidin as an emerging regulator of innate immunity in sepsis, framing the precursor form — not only the mature antimicrobial fragments — as biologically relevant in systemic inflammatory states (PMID 40806779).

How dermcidin is measured and studied

Methods used across the cited literature fall into a few broad categories:

• Biofluid quantification. Immunoassay-based measurement of dermcidin in samples such as human milk, as in the 2019 gestational diabetes comparison (PMID 31002762).
• Biophysical membrane assays. Model membrane systems used to track how peptides bind, insert and disrupt lipid bilayers, the approach behind the dermcidin-versus-LL-37 comparison (PMID 29164103).
• Microbiological and virological challenge models. Testing of dermcidin peptides against bacteria (PMID 25596890) and, in the influenza work, against a virus (PMID 41911454).
• Gene-expression and target-modulation studies. Analysis of DCD expression in tumours (PMID 18403914) and screening of small molecules that modulate dermcidin (PMID 35621952).

Summary of the cited literature

Dermcidin in Humans: What Studies Report

None of the verified papers above described an approved dermcidin product, a human dosing regimen or a clinical adverse-event profile. The work reported to date is mechanistic, observational or preclinical: biophysical membrane studies (PMID 29164103), animal and laboratory infection models (PMID 41911454), biofluid measurement in a clinical population (PMID 31002762) and early target-modulation chemistry (PMID 35621952). Readers who encounter dermcidin in a supplement or research-peptide context should note that the cited literature treats it as an endogenous molecule and a drug target, not as a characterised human therapy.

Why the term matters to peptide readers

Dermcidin is a useful case study in three respects. First, it shows that a human peptide can be constitutively secreted into a harsh external environment and still function, which shaped how researchers think about salt tolerance in antimicrobial peptides (PMID 25596890). Second, the direct comparison with LL-37 demonstrated that similar functional outcomes can arise from different membrane mechanisms (PMID 29164103). Third, the same gene has been linked to processes as different as skin defense and tumour cell survival, a reminder that peptide biology is often context-dependent rather than single-purpose (PMID 22455996, PMID 18403914).

References

• The secrets of dermcidin action (International Journal of Medical Microbiology, 2015)
• The Human Antimicrobial Peptides Dermcidin and LL-37 Show Novel Distinct Pathways in Membrane Interactions (Frontiers in Chemistry, 2017)
• The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival (Current Opinion in Clinical Nutrition and Metabolic Care, 2008)
• Dermcidin has antiviral activity and protects against influenza (PNAS, 2026)
• Chemerin and Dermcidin in Human Milk and Their Alteration in Gestational Diabetes (Journal of Human Lactation, 2019)
• Pro-Dermcidin as an Emerging Regulator of Innate Immunity in Sepsis (International Journal of Molecular Sciences, 2025)
• Preclinical Development of Seriniquinones as Selective Dermcidin Modulators for the Treatment of Melanoma (Marine Drugs, 2022)
• The multiple facets of dermcidin in cell survival and host defense (Journal of Innate Immunity, 2012)